The start of an in-human trial for bioresorbable tibial implants boosted Osteopore into the stratosphere.
Singapore-headquartered, ASX-listed bioresorbable implant company Osteopore wiped the floor with other biotechs, recording a 515% return for the month of April.
On 14 April last year Osteopore inked two non-binding term sheets with Accelerate Technologies to commercialise technology that accelerates bone and tissue regeneration.
On 22 April this year the company started its first-in-human clinical trial for knee preservation with heparan sulphate 3 and aXOpore via a high tibial osteotomy at the National University Hospital in Singapore.
Osteopore hopes to recruit about a dozen patients to establish a safety profile for aXOpore, and to investigate the product’s efficacy to enhance osteosynthesis in HTO patients.
The company’s shares are sitting at $0.40 with a market cap of almost $4.1 million.
It was daylight second, but cellular medicines company Mesoblast also had a good month, with a 172% one-month return and a share price sitting at $0.91.
Most of that jump came after the FDA said the available clinical data from its Phase 3 study MSB-GVHD001 appeared “sufficient” to support its submission for a proposed Biologics License Application (BLA) for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD).
Mesoblast said it now intended to file the resubmission during the next quarter.
Cambium Bio (one-month return of 80%), genomic life science company EZZ (77%) and Recce Pharmaceuticals (46%) rounded out the top five performers for the past month.
Firebrick Pharma has had a good week, with the launch in the US of its nasal antiseptic spray Nasodine for “nasal hygiene”. That saw it have a 25% one-week return, and 27% for the past month.
